Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center, shared on LinkedIn:
“RIBOLARIS at SABCS 2026!
Can we safely omit chemotherapy in selected patients with high-risk HR+/HER2− early breast cancer?
Looking forward to Dr. Milana Bergamino Sirvén’s presentation of updated results from the phase II SOLTI – Unicancer RIBOLARIS trial during the Rapid-Fire session (RF2-4).
An important study exploring how genomic profiling and response to neoadjuvant therapy could help personalize treatment decisions and reduce unnecessary chemotherapy.
Congratulations to the entire SOLTI-UNICANCER team and all participating investigators!
RF2-4: Genomic Response-Guided Chemotherapy Omission After Neoadjuvant Ribociclib and Endocrine Therapy in High-Risk HR+/HER2− Early Breast Cancer: Updated Results from the Phase II SOLTI-UNICANCER RIBOLARIS Trial.
See session details on the SABCS website.”
You may also find this interesting:
SABCS 2026: The Top 10 Breast Cancer Studies to Watch for Potential Practice-Changing Results
